Moderna: 2022 EPS down 29%
(CercleFinance.com) - Moderna has reported FY 2022 sales of $19.
3bn, up from $18.5bn in 2021, with business still driven by increased sales of the company's COVID-19 vaccines.
The company also says that it increased its R&D spending by 65% to $3.3bn.
As a result, net profit fell 31% to $8.4bn, while EPS was down preety much the same (-29%) at $20.12.
Copyright (c) 2023 CercleFinance.com. All rights reserved.